Incannex, an Australian pharmaceutical company, announced the first dosing in a Phase 2 study of IHL-675A, the company’s proprietary and novel combination drug candidate composed of Hydroxychloroquine Sulphate (HCQ) and cannabidiol (CBD), for the treatment of inflammatory diseases including rheumatoid arthritis (RA).

Incannex has demonstrated that IHL-675A components, HCQ and CBD, act synergistically to inhibit production of inflammatory cytokines and reduce disease severity in earlier studies.

DocWire News spoke with Dr Mark Bleackley – Chief Scientific Officer, Incannex Healthcare Inc., who spoke about this promising therapy combination, which has the potentially to positively impact people living with RA.

source